丙型肝炎病毒清除后肝细胞癌监测的持续时间与成本效益
本研究采用微观模拟模型,评估口服直接抗病毒药物治愈丙型肝炎后每半年一次肝细胞癌监测的成本效益及最佳停止年龄。结果显示,肝硬化患者监测至70岁、 stable advanced fibrosis患者监测至60岁时,增量成本效益比均低于每增加一个质量调整生命年15万美元。
要点
- 肝硬化治愈患者每半年监测至70岁,ICER为79,500–94,800美元/QALY。
- 晚期纤维化治愈患者每半年监测至60岁,ICER为124,600–129,800美元/QALY。
- 每1000例肝硬化患者监测可多检出130例早期肝癌并获51个QALY。
核心结论
- 丙型肝炎治愈后每半年肝细胞癌监测对肝硬化患者至70岁、对稳定晚期纤维化患者至60岁具有成本效益。
研究设计与样本
- 微观模拟模型模拟口服直接抗病毒药物治愈的丙型肝炎伴晚期纤维化或肝硬化患者的肝细胞癌自然史。
- 比较每半年超声联合甲胎蛋白监测5年至终身与不监测,数据来自已发表文献。
主要发现
- 肝硬化患者停止监测年龄70岁时,ICER为79,500–94,800美元/QALY,低于150,000美元/QALY,与起始年龄40–65岁无关。
- 肝硬化患者每1000人监测较不监测多检出130例极早期/早期肝细胞癌,多获51个QALY。
- 晚期纤维化患者停止监测年龄60岁时,ICER为124,600–129,800美元/QALY,低于150,000美元/QALY,与起始年龄40–50岁无关。
- 晚期纤维化患者每1000人监测较不监测多检出24例极早期/早期肝细胞癌,多获12个QALY。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Successful treatment of chronic hepatitis C with oral direct-acting antivirals (DAAs) leads to virological cure, however, the subsequent risk of hepatocellular carcinoma (HCC) persists. Our objective was to evaluate the cost-effectiveness of biannual surveillance for HCC in patients cured of hepatitis C and the optimal age to stop surveillance. METHODS: We developed a microsimulation model of the natural history of HCC in individuals with hepatitis C and advanced fibrosis or cirrhosis who achieved virological cure with oral DAAs. We used published data on HCC incidence, tumor progression, real-world HCC surveillance adherence, and costs and utilities of different health states. We compared biannual HCC surveillance using ultrasound and alpha-fetoprotein for varying durations of surveillance (from 5 years to lifetime) vs. no surveillance. RESULTS: In virologically cured patients with cirrhosis, the incremental cost-effectiveness ratio (ICER) of biannual surveillance remained below $150,000 per additional quality-adjusted life year (QALY) (range: $79,500-$94,800) when surveillance was stopped at age 70, irrespective of the starting age (40-65). Compared with no surveillance, surveillance detected 130 additional HCCs in 'very early'/early stage and yielded 51 additional QALYs per 1,000 patients with cirrhosis. In virologically cured patients with advanced fibrosis, the ICER of biannual surveillance remained below $150,000/QALY (range: $124,600-$129,800) when surveillance was stopped at age 60, irrespective of the starting age (40-50). Compared with no surveillance, surveillance detected 24 additional HCCs in 'very early'/early stage and yielded 12 additional QALYs per 1,000 patients with advanced fibrosis. CONCLUSION: Biannual surveillance for HCC in patients cured of hepatitis C is cost-effective until the age of 70 for patients with cirrhosis, and until the age of 60 for patients with stable advanced fibrosis. LAY SUMMARY: Individuals who are cured of hepatitis C using oral antiviral drugs remain at risk of developing liver cancer. The value of lifelong screening for liver cancer in these individuals is not known. By simulating the life course of hepatitis C cured individuals, we found that ultrasound-based biannual screening for liver cancer is cost-effective up to age 70 in those with cirrhosis and up to age 60 in those with stable advanced fibrosis.
引用
- Mueller PP, Chen Q, Ayer T, et al. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. J Hepatol. 2022. PMID: 35157959. doi:10.1016/j.jhep.2022.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。